Trial Profile

A phase III study of andexanet alfa as a reversal agent for edoxaban

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Andexanet alfa (Primary)
Indications Haemorrhage
Focus Registrational; Therapeutic Use
Acronyms ANNEXA-E
Sponsors Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals

Most Recent Events

06 May 2015 According to a Portola Pharmaceuticals media release, final data from this and the other two phase III ANNEXA studies (see profiles 700242840 and 700238727) is expected to be presented in 2015.
12 Aug 2014 New trial record
06 Aug 2014 Portola Pharmaceuticals plans to initiate ANNEXA-E registration studies in 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com